CRRTInfO: Filter Lifespan in Continuous Renal Replacement Therapy
Study Details
Study Description
Brief Summary
The only supportive therapy for patients with AKI is renal replacement therapy (RRT). In the ICU setting, continuous RRT (CRRT) is mostly favored. In a post-hoc analysis of the RICH trial (regional citrate versus systemic heparin anticoagulation for CRRT in critically ill patient with AKI), it was shown that the filter life span is associated with an increased rate of new infection and that the type of anticoagulants did not directly affect infection rate. The mechanisms of this infection rate is unknown.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Approximately every second patient in the ICU suffers from acute kidney injury (AKI) which complicates the clinical course of these patients. Continuous renal replacement therapy (CRRT) has become the most widely used form of renal support in critically ill patients as it allows continuous, controlled removal of fluids and is hemodynamically better tolerated compared to intermittent dialysis. The requirement for intravascular access and artificial circuits may increase the risk of infection. However, there are no studies analyzing the incidence and characteristics of infections in critically ill patients with CRRT or the implications for outcome. Therefore, this observational trial investigates the factors that influences new onset infection in critically ill patients with CRRT.
Study Design
Outcome Measures
Primary Outcome Measures
- Number of new infections since start of dialysis [From start of dialysis until day 28]
Secondary Outcome Measures
- Number of new blood stream infections [From start of dialysis until day 28]
- Number of new pneumonia [From start of dialysis until day 28]
- Number of new urinary tract infection [From start of dialysis until day 28]
- Number of new catheter blood stream infection [From start of dialysis until day 28]
- Number of new other infections [From start of dialysis until day 28]
- Filter live span [From start of dialysis until day 28 or end of CRRT, whatever occurs first]
- Number of bacterial contamination of t he CRRT circuit proven by culture [From start of dialysis until day 28 or end of CRRT, whatever occurs first]
- Down-time of CRRT in hours [From start of dialysis until day 28 or end of CRRT, whatever occurs first]
- Days on renal replacement therapy [From start of dialysis until day 28]
- Duration of mechanical ventilation in hours [From start of dialysis until day 28]
- Number of bleeding complications [From start of dialysis until day 28]
defined as bleeding with the need for at least 1 packed red cells (RBC)
- Recovery of kidney function [At day 28 after start of dialysis]
Recovery of kidney function (defined as complete recovery: serum-creatinine ≤0.5 mg/dl higher than baseline; partial recovery: serum creatinine >0.5 mg/dl higher than baseline but no dialysis-dependence; non-recovery: patients who remained dialysis-dependent)
- Recovery of kidney function [At day 60 after start of dialysis]
Recovery of kidney function (defined as complete recovery: serum-creatinine ≤0.5 mg/dl higher than baseline; partial recovery: serum creatinine >0.5 mg/dl higher than baseline but no dialysis-dependence; non-recovery: patients who remained dialysis-dependent)
- Recovery of kidney function [At day 90 after start of dialysis]
Recovery of kidney function (defined as complete recovery: serum-creatinine ≤0.5 mg/dl higher than baseline; partial recovery: serum creatinine >0.5 mg/dl higher than baseline but no dialysis-dependence; non-recovery: patients who remained dialysis-dependent)
- Number of patients with need for kidney replacement therapy [At day 28 after start of dialysis]
- Number of patients with need for kidney replacement therapy [At day 60 after start of dialysis]
- Number of patients with need for kidney replacement therapy [At day 90 after start of dialysis]
- Mortality [At day 28 after start of dialysis]
- Mortality [At day 60 after start of dialysis]
- Mortality [At day 90 after start of dialysis]
- Major adverse kidney events (MAKE) [At day 28 after start of dialysis]
Composite endpoint consisting of death, renal replacement therapy, and persistent renal dysfunction
- Major adverse kidney events (MAKE) [At day 60 after start of dialysis]
Composite endpoint consisting of death, renal replacement therapy, and persistent renal dysfunction
- Major adverse kidney events (MAKE) [At day 90 after start of dialysis]
Composite endpoint consisting of death, renal replacement therapy, and persistent renal dysfunction
Other Outcome Measures
- Transmigration of neutrophils [At initiation of dialysis]
- Transmigration of neutrophils [24 hours after initiation of dialysis]
- Transmigration of neutrophils [48 hours after initiation of dialysis]
- Transmigration of neutrophils [72 hours after initiation of dialysis]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Adult patients (age ≥18 years)
-
Critically ill patients with dialysis-dependent AKI
-
Continuous renal replacement therapy (CRRT)
-
Written informed consent
Exclusion Criteria:
-
Chronic kidney disease with estimated glomerular filtration rate (eGFR)<30ml/min/1.73m2
-
Chronic dialysis dependency
-
Kidney transplant
-
(Glomerulo-)nephritis, interstitial nephritis, vasculitis
-
Patients on immunosuppression
-
Patients with chronic inflammatory diseases (e.g. arthritis, HIV, chronic hepatitis)
-
Persons with any kind of dependency on the investigator or employed by the sponsor or investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | University Hospital Muenster | Muenster | Germany | D-48149 |
Sponsors and Collaborators
- University Hospital Muenster
- Baxter Healthcare Corporation
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 10-AnIt-21